Abbott has received approval from Japan’s Ministry of Health, Labor and Welfare for the company’s MitraClip, making it the first minimally invasive device to treat people in Japan with mitral regurgitation (MR) heart disease.
A group advocating on behalf of those suffering from Alzheimer's has a word for Microsoft founder Bill Gates, who recently announced he's investing $100 million in disease research: Welcome to the fight.
Cardiac patients who received XIENCE stents reported a good quality of life and felt better sooner compared to those who underwent open-heart surgery, researchers said at a recent conference in Denver.
AbbVie plans to present data from 38 abstracts of Humira (adalimumab) and other products in the company’s investigational immunology medicine portfolio at the 2017 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) annual meeting Nov. 3-8, in San Diego.
Abbott said its Confirm Rx Insertable Cardiac Monitor (ICM), a smartphone compatible ICM to help physicians identify cardiac arrhythmias remotely, has been cleared by the U.S. Food and Drug Administration (FDA).
Abbott recently said its Proclaim DRG Neurostimulator System, which stimulates dorsal root ganglion (DRG) and eases pain in patients with complex regional pain syndrome (CRPS) of the lower limbs, has been launched in the U.S.
Patients in Japan with hepatitis C virus (HCV) infection have a new eight-week treatment available now that the Japanese Ministry of Health, Labour and Welfare has approved Maviret (glecaprevir/pibrentasvir), AbbVie said in a release.